Global

Is getting more clarity on Brexit ramifications for pharma and European public health really at the top of new-year to-do lists?

Pharm Exec details the latest approaches to combating disease and health crises on a global scale-including industry perspectives from those involved on the front lines.

Amid a widening net of health threats worldwide, alliances forged in research and response may be more critical than ever to stem the tide.

New action plan urges tighter alignment of public health policy with the development of targeted therapies.

The Chinese government's “Healthy China” plan presents an unprecedented opportunity for the US healthcare industry and its investors, writes Steven Shill.

UK commentators point to job losses and disruption to patients following news that the European Medicines Agency (EMA) will be relocated to Amsterdam.

Allergan's CEO Brent Saunders explains why the European Medicines Agency should choose Dublin as its headquarters after leaving London.

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.

With its convergence of healthcare talent and tech, the nation is turning into a prime destination for innovative startups.

A year after the Accelerated Access Review explored how to speed up adoption of innovation across the NHS in England, the UK Government has responded. Leela Barham reports.

While most pharma companies are in partial production using generators, few are operating at 100% capacity, writes Jill Wechsler.

Can health stakeholders be friends without being captives?

European Commission talks drug industry investment, health issues during State of the Union.

The UK's Association of the British Pharmaceutical Industry (ABPI) had hoped to stop a new policy that amounts to price negotiation and potentially delaying access to some new medicines but its request has been denied by the High Court.

Emerging as a bastion of peace, stability, and resilience in a region increasingly beset by political turbulence and economic stagnation, Colombia has been steadily reinventing itself as a Latin American pioneer and pacesetter, including in the world of healthcare.

Leela Barham looks at the reasons behind the Association of the British Pharmaceutical Industry's bid to legally challenge NICE's proposed introduction of the budget impact test.

With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Following the unveiling of the UK’s post-Brexit life sciences strategy, Neil Grubert looks at the measures related to market access, a particular challenge in the UK market and key to its future success in the sector.

Reflector asks if the UK's newly announced post-Brexit life sciences strategy report is worth a look as a springboard to addressing future EU ties in healthcare, or just more bluster?